BridgeBio developing therapies with Columbia University, Mount Sinai

By The Science Advisory Board staff writers

October 29, 2021 -- BridgeBio Pharma announced it is collaborating with Columbia University and Mount Sinai Health System to develop potential therapies to treat individuals with genetic diseases and cancers.

The company has initiated 25 collaborations with leading institutions around the world that are focused on providing therapeutic options to patients with unmet needs.

BridgeBio noted Columbia University and Mount Sinai's respective expertise in developing breakthroughs for patients with genetic diseases and genetically driven cancers.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.